Retension Pharmaceuticals upsized IPO priced at $45 million
Retension Pharmaceuticals priced an upsized IPO at the midpoint of expectations, raising $45 million, and said its shares will begin trading Friday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Retension Pharmaceuticals prices upsized IPO at $12 a share
Retension Pharmaceuticals priced its upsized initial public offering at $12.00 a share for 3,750,000 common shares. The company expects gross proceeds of $45.0 million before expenses and says trading should begin on Oct. 9 on Nasdaq under RTSN.